1. Home
  2. MLYS vs EE Comparison

MLYS vs EE Comparison

Compare MLYS & EE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$29.27

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Logo Excelerate Energy Inc.

EE

Excelerate Energy Inc.

HOLD

Current Price

$36.35

Market Cap

1.2B

Sector

Utilities

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLYS
EE
Founded
2019
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Oil/Gas Transmission
Sector
Health Care
Utilities
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
1.2B
IPO Year
2023
2022

Fundamental Metrics

Financial Performance
Metric
MLYS
EE
Price
$29.27
$36.35
Analyst Decision
Strong Buy
Buy
Analyst Count
7
5
Target Price
$48.67
$39.20
AVG Volume (30 Days)
988.0K
340.1K
Earning Date
05-06-2026
05-06-2026
Dividend Yield
N/A
0.96%
EPS Growth
37.43
0.79
EPS
N/A
0.37
Revenue
N/A
$1,228,263,000.00
Revenue This Year
N/A
$23.59
Revenue Next Year
N/A
$24.37
P/E Ratio
N/A
$95.97
Revenue Growth
N/A
44.26
52 Week Low
$12.59
$21.29
52 Week High
$47.65
$43.18

Technical Indicators

Market Signals
Indicator
MLYS
EE
Relative Strength Index (RSI) 55.39 59.96
Support Level $26.01 $35.10
Resistance Level $31.12 $43.18
Average True Range (ATR) 1.63 1.45
MACD 0.12 0.24
Stochastic Oscillator 73.51 96.19

Price Performance

Historical Comparison
MLYS
EE

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

About EE Excelerate Energy Inc.

Excelerate Energy Inc offers LNG solutions, providing integrated services along the LNG value chain. It offers a full range of regasification services, from FSRUs to infrastructure development, to LNG and natural gas supply. Its business spans the globe, with a regional presence in 11 countries and an operational presence in Argentina, Bangladesh, Brazil, Finland, Germany, Pakistan, the United Arab Emirates (UAE), and the United States.

Share on Social Networks: